Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00379470 · ClinicalTrials.gov registry record · Phase 3
Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)
A Phase 3 study of Recurrent Glioblastoma Multiforme, sponsored by NovoCure.
- Completed
- Registry status
- Phase 3
- Development phase
- 236
- Enrollment target
- 20
- Study locations
NCT00379470: Completed Phase 3 study of Recurrent Glioblastoma Multiforme, sponsored by NovoCure.
NCT00379470 is a Phase 3 study of Recurrent Glioblastoma Multiforme that has completed, run by NovoCure. The registered enrollment target is 236 participants, above the 64-participant average among 6 other Recurrent Glioblastoma Multiforme trials with a reported enrollment target (269% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00379470, a Phase 3 study of Recurrent Glioblastoma Multiforme, has completed, sponsored by NovoCure.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 236 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is a randomized, controlled trial, designed to test the efficacy and safety of a new medical device, the NovoTTF-100A. The device is an experimental, portable, battery operated device for chronic treatment of patients with recurrent or progressive glioblastoma multiforme (GBM) using alternating electric fields (termed TTFields).
Conditions Studied
Interventions
- DEVICE NovoTTF-100A
Study Locations (20)
Other
- University Hospital Graz - Graz
- FN Brno - Masaryk University - Brno
- Na Homolce Hospital - Prague
- Hospital of Neurology Lyon - University Claude Bernard Lyon 1 - Lyon
- Group Hospitals Pitie-Salpetriere - Paris
Illinois
- Northwestern University - Chicago
- University of Illinois in Chicago - Chicago
- Evanston Northwestern Healthcare - Evanston
Massachusetts
- Boston University Medical Center - Boston
- Beth Israel Deaconess Medical Center - Boston
- Lahey Clinic Medical Center - Burlington
New York
- Memorial Sloan Kettering Cancer Center - New York
- Weill Cornell Medical College - New York
- Columbia University Medical Center - New York
Ohio
- University Hospitals of Cleveland - Cleveland
- Cleveland Clinic - Cleveland
New Jersey
- NJ Neuroscience Institute - JFK Medical Center - Edison
Pennsylvania
- University of Pittsburgh Medical Center (UPMC) - Pittsburgh
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2006-09 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
What the finished NCT00379470 record still lists
NCT00379470 is an interventional study that assigns participants to a tested intervention. The registered 236 participants enrollment target is mid-sized for trials with a published cap, above the 64-participant average among 6 other Recurrent Glioblastoma Multiforme trials with a reported enrollment target (269% higher).
The record links to 1 condition, with Recurrent Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which NovoTTF-100A is the first listed.
NCT00379470 names 20 study sites across 9 states, led by Other, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00379470 about?
NCT00379470 is a clinical study titled "Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)". The study is a randomized, controlled trial, designed to test the efficacy and safety of a new medical device, the NovoTTF-100A. The device is an experimental, portable, battery operated device for chronic treatment of patients with recurrent or progressive glioblastoma multiforme (GBM) using altern...
What is the current status of trial NCT00379470?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 236 participants. The study started on 2006-09. Estimated completion is 2011-01.
What conditions does trial NCT00379470 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma Multiforme.
What interventions are being tested in trial NCT00379470?
The interventions under investigation include: NovoTTF-100A (DEVICE).
Who is sponsoring clinical trial NCT00379470?
This trial is sponsored by NovoCure, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00379470 being conducted?
This trial has 20 study locations across Illinois, Massachusetts, New Jersey, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
RECRUITING · Phase 1
-
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
ACTIVE NOT RECRUITING · Phase 1
-
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
COMPLETED · Phase 1
-
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
COMPLETED · Phase 2
-
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
COMPLETED · Phase 2
-
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04995341 · 236 participants · NA
Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)
- NCT05822362 · 236 participants · Phase 2
CBD for Individuals at Risk for Alzheimer's Disease
- NCT06200103 · 236 participants · Phase 2
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
- NCT06494072 · 236 participants · Phase 4
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia